Precigen (PGEN) Competitors $3.91 -0.17 (-4.17%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$3.95 +0.04 (+1.02%) As of 10/22/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. MENS, KYMR, AKRO, NAMS, CRNX, GMTX, LNTH, VKTX, PRAX, and MIRMShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Akero Therapeutics (AKRO), NewAmsterdam Pharma (NAMS), Crinetics Pharmaceuticals (CRNX), Gemini Therapeutics (GMTX), Lantheus (LNTH), Viking Therapeutics (VKTX), Praxis Precision Medicines (PRAX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Its Competitors Jyong Biotech Kymera Therapeutics Akero Therapeutics NewAmsterdam Pharma Crinetics Pharmaceuticals Gemini Therapeutics Lantheus Viking Therapeutics Praxis Precision Medicines Mirum Pharmaceuticals Jyong Biotech (NASDAQ:MENS) and Precigen (NASDAQ:PGEN) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk. Do insiders and institutionals hold more shares of MENS or PGEN? 33.5% of Precigen shares are held by institutional investors. 47.1% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend MENS or PGEN? Precigen has a consensus target price of $8.25, suggesting a potential upside of 111.00%. Given Precigen's stronger consensus rating and higher possible upside, analysts clearly believe Precigen is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Precigen 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer MENS or PGEN? In the previous week, Precigen had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for Precigen and 1 mentions for Jyong Biotech. Precigen's average media sentiment score of 0.45 beat Jyong Biotech's score of 0.00 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, MENS or PGEN? Jyong Biotech has higher earnings, but lower revenue than Precigen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/APrecigen$3.92M297.21-$126.24M-$0.42-9.31 Is MENS or PGEN more profitable? Jyong Biotech has a net margin of 0.00% compared to Precigen's net margin of -2,868.66%. Jyong Biotech's return on equity of 0.00% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Precigen -2,868.66%-842.83%-78.98% SummaryPrecigen beats Jyong Biotech on 8 of the 11 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$3.47B$6.16B$10.67BDividend YieldN/A2.24%5.72%4.86%P/E Ratio-9.3122.9129.1027.13Price / Sales297.21463.56584.37126.20Price / CashN/A45.5937.1261.42Price / Book30.0810.2912.186.43Net Income-$126.24M-$52.53M$3.33B$276.63M7 Day Performance12.03%-0.60%-0.74%-0.77%1 Month Performance5.39%10.30%5.32%0.68%1 Year Performance315.91%13.51%68.16%32.03% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen4.3396 of 5 stars$3.91-4.2%$8.25+111.0%+317.2%$1.22B$3.92M-9.31190MENSJyong BiotechN/A$59.01+0.0%N/AN/A$4.49BN/A0.0031Positive NewsKYMRKymera Therapeutics1.7603 of 5 stars$60.50+1.1%$62.74+3.7%+15.4%$4.33B$47.07M-17.44170News CoverageUpcoming EarningsAnalyst ForecastAKROAkero Therapeutics3.8422 of 5 stars$53.91+0.1%$73.38+36.1%+81.2%$4.31BN/A-26.9630Positive NewsNAMSNewAmsterdam Pharma3.601 of 5 stars$37.66+3.5%$43.20+14.7%+85.0%$4.24B$45.56M-23.254Trending NewsAnalyst ForecastAnalyst RevisionCRNXCrinetics Pharmaceuticals4.3355 of 5 stars$42.45+2.1%$74.45+75.4%-32.2%$4.00B$1.04M-10.33210Positive NewsGMTXGemini TherapeuticsN/A$89.94+21.0%N/A+69.2%$3.90BN/A-89.9430High Trading VolumeLNTHLantheus4.5902 of 5 stars$56.60+1.8%$74.50+31.6%-49.3%$3.85B$1.53B15.05700VKTXViking Therapeutics3.7799 of 5 stars$33.75+0.7%$86.42+156.0%-49.3%$3.79BN/A-22.0620Earnings ReportPRAXPraxis Precision Medicines2.178 of 5 stars$175.07-7.9%$222.36+27.0%+155.3%$3.71B$8.55M-14.24110Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeMIRMMirum Pharmaceuticals3.8706 of 5 stars$73.03-0.7%$79.70+9.1%+75.4%$3.67B$336.89M-60.35140 Related Companies and Tools Related Companies MENS Competitors KYMR Competitors AKRO Competitors NAMS Competitors CRNX Competitors GMTX Competitors LNTH Competitors VKTX Competitors PRAX Competitors MIRM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
